Alpha-9 Oncology
Megan Bumgarner is currently working at Alpha-9 Oncology as an Associate Director CMC Operations where Megan manages CMOs for radiopharmaceutical drug product clinical manufacturing and designs experiments for formulation development. Megan has a strong background in operations management and engineering, having previously worked at BD in various roles such as Manufacturing Engineering Manager, Senior Manufacturing Engineer, and Operations Manager. Before that, Megan held positions at InVivo Therapeutics as a Senior Process Development Engineer and MIT Prather Lab as a UROP. Megan holds a Bachelor of Science in Chemical Engineering from Massachusetts Institute of Technology and a Master of Business Administration from Isenberg School of Management, UMass Amherst.
Alpha-9 Oncology
Alpha-9 Oncology is a clinical stage, radiopharmaceutical company developing differentiated and highly targeted radiopharmaceuticals with the potential to meaningfully improve the treatment of people living with cancer. Applying proprietary technologies and deep-foundational expertise, Alpha-9 is on the forefront of engineering bespoke radiopharmaceuticals that are optimized to selectively deliver radiation to tumor sites while minimizing off-target effects. Alpha-9 is advancing a robust pipeline of novel radiopharmaceuticals with a systematic approach to molecule design that offers broad potential for expansion into several validated oncology targets. Alpha-9 was founded by researchers from the University of British Columbia and BC Cancer, with the goal of improving the lives of patients affected by metastatic cancers.